Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?

Philip Barter1, Kerry-Anne Rye

  • 1The Heart Research Institute, 7 Eliza Street, Newtown, Sydney 2042, Australia. barterp@hri.org.au

Insights

Cholesteryl ester transfer protein (CETP) inhibitors aim to raise HDL-C for cardiovascular disease prevention. Newer CETP inhibitors are being tested in clinical trials to re-evaluate their efficacy and safety.

Area of Science:

  • Cardiovascular medicine
  • Pharmacology
  • Lipid metabolism

Background:

  • Elevated low-density lipoprotein-cholesterol (LDL-C) and reduced high-density lipoprotein-cholesterol (HDL-C) are key risk factors for cardiovascular disease (CVD).
  • Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl esters from HDL to other lipoproteins, influencing lipid profiles.
  • Inhibiting CETP is a strategy to increase HDL-C levels and potentially reduce CVD risk.

Purpose of the Study:

  • To re-evaluate the anti-atherogenic potential of CETP inhibitors.
  • To assess the safety and efficacy of CETP inhibitors that lack the adverse off-target effects of earlier agents like torcetrapib.

Main Methods:

  • Clinical outcome trials are underway with novel CETP inhibitors, specifically dalcetrapib and anacetrapib.
  • These trials aim to determine if CETP inhibition, without torcetrapib's off-target effects, proves beneficial in preventing cardiovascular events.

Main Results:

  • Previous CETP inhibitor torcetrapib was associated with increased mortality and cardiovascular events, possibly due to off-target effects.
  • Current trials with dalcetrapib and anacetrapib are designed to isolate the effects of CETP inhibition itself.

Conclusions:

  • The hypothesis that CETP inhibitors are anti-atherogenic is being re-examined with newer agents.
  • Ongoing clinical trials will provide crucial data on the cardiovascular benefits and risks of selective CETP inhibition.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...